| Market Cap | ₹18,500Cr |
| ROE | 7.25% |
| P/E Ratio(TTM) | 39.00 |
| EPS(TTM) | 29.78 |
| P/B Ratio | 2.81 |
| Dividend Yield | 0.43% |
| Industry P/E | 34.72 |
| Book Value | 413.79 |
| Debt to Equity | 0.44 |
| Face Value | 1 |
| Parent Organisation | Jubilant Pharmova Limited |
| Managing Director | Mr. Arjun Bhartia |
| NSE Symbol | JUBLPHARMA |
| FUND NAME | AUM(%) |
|---|---|
| Bandhan Focused Fund Direct Growth | 4.13% |
| Kotak Contra Fund Direct Growth | 1.32% |
| Bandhan Small Cap Fund Direct Growth | 1.16% |
| Quant Small Cap Fund Direct Plan Growth | 1.09% |
| COMPANY | 52 WEEK | MARKET PRICE | P/E Ratio | |
|---|---|---|---|---|
| Divi's Laboratories | NA (0.00%) | 79.27 | ||
| Neuland Laboratories | NA (0.00%) | 127.85 | ||
| Acutaas Chemicals | NA (0.00%) | 64.21 | ||
| Gujarat Themis Biosyn | NA (0.00%) | 109.89 |